Novo Nordisk rises as 4th-qtr beats expectations

3 February 2021

Shares of Danish diabetes care giant Novo Nordisk (NOV: N) were up 4.6% at 458.25 Danish kroner mid-morning, after the company announce financial results for the fourth quarter and full-year 2020.

Net profit for the quarter rose 6.9% to 9.32 billion Danish kroner ($1.51 billion) from 8.72 billion kroner a year earlier, above the 9.08 billion kroner forecast by analysts in a FactSet poll. Sales slipped 0.9% to 32.14 billion kroner, but better than analysts' expectations of 31.85 billion kroner.

For full-year 2020,Novo Nordisk’s sales increased 4% (7% at constant currency) to 126.9 billion kroner. Net profit for the year was up 8% at 42.14 billion kroner, with diluted earnings per share (EPS) rising 10% to 18.02 kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK